ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has an average broker rating of 3, which is interpreted as a Hold, as rated by 5 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 3 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) : The highest level ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is projected to reach is $21 for the short term and the lowest estimate is at $7. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $14 and the possibility the share price can swing is $9.9.
Company shares have received an average consensus rating of Hold for the current week Also, Raymond James initiates coverage on ZIOPHARM Oncology Inc (NASDAQ:ZIOP). The rating major has initiated the coverage with market perform rating on the shares. The rating by the firm was issued on June 2, 2016.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP): stock turned positive on Tuesday. Though the stock opened at $5.41, the bulls momentum made the stock top out at $5.62 level for the day. The stock recorded a low of $5.41 and closed the trading day at $5.58, in the green by 5.08%. The total traded volume for the day was 1,926,161. The stock had closed at $5.31 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged that Belbel Caesar J, officer (COO, CLO, and Secretary) of Ziopharm Oncology Inc, had unloaded 153,333 shares at an average price of $12.84 in a transaction dated on November 19, 2015. The total value of the transaction was worth $1,968,796.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).